AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2008-03-14
Target enrollment:
Participant gender:
Summary
This is a Phase 2 study being conducted at multiple centers in the United States, Europe and
Canada. Patients having pancreatic cancer that is locally advanced or that has spread to
other parts of the body (i.e., metastatic) are eligible to participate. Patients must have
not had any prior systemic treatment for advanced disease. The purpose of the study is to
test whether the angiogenesis inhibitor Axitinib [AG-013736] in combination with gemcitabine
is an effective treatment for advanced pancreatic cancer vs. gemcitabine alone by overall
survival.